Abnormalities of fibrinolysis in essential hypertension. 1984

M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak

A highly-standardized plate method was used to study fibrinolytic profiles in 14 patients with essential hypertension and 245 normotensive healthy control subjects. Compared with the normotensive group, the group with essential hypertension showed a defect in fibrinolysis, as evidenced by a significant increase in the mean level of inhibitor of plasminogen activation, and a subset of the hypertensive patients also showed a significant decrease in the mean level of vascular plasminogen activator. There were no significant differences between the two groups in relation to plasma fibrinogen level, total fibrinolytic activity and plasmin inhibitor. The alterations in inhibitor of plasminogen activation and vascular plasminogen activator in the patients with essential hypertension may reflect a defect in the fibrin-clearing mechanism and, perhaps, contribute to the vascular complications of hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated

Related Publications

M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
January 1973, Bollettino della Societa italiana di cardiologia,
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
January 2011, Current pharmaceutical design,
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
November 1998, Lancet (London, England),
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
July 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation,
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
June 1989, Presse medicale (Paris, France : 1983),
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
August 1983, Clinical science (London, England : 1979),
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
January 1986, Annals of the New York Academy of Sciences,
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
May 2007, The Journal of pediatrics,
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
June 2012, Internal and emergency medicine,
M M Ettenger, and E P MacCarthy, and P Glas-Greenwalt, and D H Clyne, and V E Pollak
February 1988, Experientia,
Copied contents to your clipboard!